Integrating synthetic immunology, multiplexing CRISPR, and cell analysis tools to accelerate the development of CAR-T therapies

Cell and gene therapies provide novel medicines to treat cancer patients and since the first CAR-T therapy was approved in 2017, five further CAR-T therapies have become available to treat hematological malignancies.  However, the development of safe and effective cellular therapies remains a long and costly process.

In this webinar, our speakers, Dr. Justin Eyquem (UCSF) and Dr. Yongyang Huang (Revvity) will present strategies to accelerate CAR-T therapy development by integrating advanced tools - multiplexing CRISPR gene editing, ISO standard-based cell counting and analysis methods, and synthetic biology approaches - to ensure the quality and control the variation of cell therapies, CAR-T or HLA-Independent TCR-T cells. Dr. Eyquem will also describe a novel peptide-based method to effectively deliver a gene of interest to primary immune T cells without electroporation.
 
Watch now!

For research use only. Not for use in diagnostic procedures.